Keyphrases
Allelic Variation
20%
Alzheimer's Disease Neuroimaging Initiative
40%
Asymptomatic Carriers
20%
Asymptomatic mutation Carriers
40%
Australia
20%
Brain Atrophy
20%
Brain-derived Neurotrophic Factor
40%
Brain-derived Neurotrophic Factor Val66Met
100%
Cerebrospinal Fluid
40%
Cerebrospinal Fluid Samples
40%
Clinical Assessment
20%
Clinical Disease
20%
Clinical Site
20%
Clinical Symptoms
20%
Cognitive Assessment
20%
Cognitive Composite
20%
Cognitive Decline
20%
Cognitive Impairment
20%
Cognitive Level
20%
Cognitively Normal Older Adults
40%
Cross-sectional Cohort Study
20%
Disease Stage
20%
Dominantly Inherited Alzheimer Network
40%
Dominantly Inherited Alzheimer's Disease
100%
Episodic Memory
60%
Fluid Level
20%
Global Cognition
20%
Hippocampal Volume
20%
Homozygote
40%
Immunoassay
40%
Mass Spectrometry
60%
Mass Spectrometry Analysis
20%
Mutation Carriers
20%
Neurotrophic Support
20%
Non-carriers
20%
Occupancy
40%
Occupancy Ratio
20%
P-tau217
60%
Pharmacological Strategies
20%
Phosphorylated tau181
80%
Phosphorylation
20%
Phosphorylation State
20%
Sporadic AD
40%
Tau Hyperphosphorylation
100%
Tau Levels
20%
Tau Phosphorylation
80%
Threonine
40%
Total tau
80%
United Kingdom
20%
United States
20%
Val66Met Polymorphism
20%
Neuroscience
Alzheimer's Disease
100%
Amyloid Protein
14%
Brain-Derived Neurotrophic Factor
100%
Cognitive Disorders
14%
Episodic Memory
42%
Hyperphosphorylation
100%
Immunoassay
28%
Mass Spectrometry
57%
Threonine
28%
Biochemistry, Genetics and Molecular Biology
Amyloid Protein
6%
Brain-Derived Neurotrophic Factor
100%
Cerebrospinal Fluid Level
6%
Cohort Study
6%
Episodic Memory
18%
Homozygote
12%
Hyperphosphorylation
100%
Immunoassay
12%
Liquid
18%
Mass Spectrometry
18%
Mass Spectrometry
6%
Tau
100%
Threonine
12%